Opioid Use Disorder in Two Samples of the Lebanese Population: Scale Validation and Correlation with Sleep and Mood Disorders

Author:

Chamoun Karam1,Mouawad Joseph1,Salameh Pascale2,Sacre Hala3,Haddad Ramzi4,Khabbaz Lydia Rabaa1,Megarbane Bruno5,Hajj Aline1

Affiliation:

1. Saint Joseph University

2. Lebanese American University

3. INSPECT-LB (Institut National de Santé Publique, d’Épidémiologie Clinique et de Toxicologie- Liban)

4. Lebanese University

5. Inserm, UMR-S1144, Université Paris Cité

Abstract

Abstract Background: The revised Opioid Risk Tool (ORT-OUD) is a brief, self-report scale designed to provide clinicians with a simple, validated method to screen for the risk of developing an Opioid Use Disorder (OUD) in patients without a prior history of substance abuse. This study aimed to translate and validate the Arabic version of ORT-OUD in the Lebanese population and assess its clinical validity in a sample of patients with OUD. Methods: This cross-sectional study in the Lebanese population used several validated scales to assess the risk of OUD, including the Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST). Other tools evaluated chronotype and sleep and mood disturbances. Principal component analysis with Varimax rotation was applied to assess ORT-OUD construct validity. Convergent validity with the Arabic version of ASSIST was evaluated. The ORT-OUD criterion validity was then assessed in a clinical sample of patients with OUD. Results: This study included 581 participants. The prevalence of the OUD risk in the Lebanese population using the ORT-OUD scale and the ASSIST-opioids scale was estimated at 14.5% and 6.54%, respectively. No items of the ORT-OUD were removed; all items converged over a solution of four factors with an eigenvalue>1, explaining a total of 68.2% of the variance (Cronbach’s alpha=0.648). The correlation coefficients between the ORT-OUD total score and ASSIST subscales were as follows: ASSIST-opioids (r=0.174; p=<0.001), ASSIST-sedatives (r=0.249; p <0.001), and ASSIST-alcohol (r=0.161; p=<0.001). ORT-OUD clinical validation showed a correlation with ASSIST-opioids (r=0.251; p=0.093) and ASSIST-sedatives (r=0.598; p<0.001). Higher ORT-OUD scores were associated with a family and personal history of alcohol and substance consumption and higher insomnia and anxiety scores. Conclusion: This study is the first to validate the Arabic version of ORT-OUD in the Lebanese population, an essential step towards improving the detection and management of OUD in this population.

Publisher

Research Square Platform LLC

Reference76 articles.

1. Scholl L. Drug and Opioid-Involved Overdose Deaths — United States, 2013–2017. MMWR Morb Mortal Wkly Rep [Internet]. 2019 [cited 2020 Jan 15];67. Available from: https://www.cdc.gov/mmwr/volumes/67/wr/mm675152e1.htm

2. Mood/Anxiety disorders and their association with non-medical prescription opioid use and prescription opioid use disorder: longitudinal evidence from the National Epidemiologic Study on Alcohol and Related Conditions;Martins SS;Psychol Med

3. Drogues illicites au Liban. : analyse des politiques et des pratiques [Internet]. Drogues, santé et société. 2020 [cited 2022 Dec 19]. Available from: https://drogues-sante-societe.ca/drogues-illicites-au-liban-analyse-des-politiques-et-des-pratiques/

4. Ghandour LA, El Sayed DS, Martins SS. Prevalence and Patterns of Commonly Abused Psychoactive Prescription Drugs in a Sample of University Students from Lebanon: An Opportunity for Cross-Cultural Comparisons. Drug Alcohol Depend. 2012 Feb 1;121(0):110–7.

5. Tourbah SG. Report on opioid consumption and number of patients treated. Service des Stupéfiants, Dpt. de Pharmacie. Lebanon: Ministère de la Santé publique; 2001 Nov.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3